LATISSE

This brand name is authorized in Brazil, Canada, New Zealand, United States

Active ingredients

The drug LATISSE contains one active pharmaceutical ingredient (API):

1 Bimatoprost
UNII QXS94885MZ - BIMATOPROST

Bimatoprost is a potent ocular hypotensive agent. It is a synthetic prostamide, structurally related to prostaglandin F (PGF), that does not act through any known prostaglandin receptors.

Read about Bimatoprost

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
LATISSE Eyes drops, solution FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
S01EE03 Bimatoprost S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EE Prostaglandin analogues
Discover more medicines within S01EE03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 501006901131310
Country: CA Health Products and Food Branch Identifier(s): 02350939
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 13943
Country: US FDA, National Drug Code Identifier(s): 0023-3616

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.